Ethics approval and consent to participate
Written informed consent for publication of their clinical details and/or clinical images was obtained from the parent of the patient. A copy of the consent form is available for review by the Editor of this journal.
The off-label use of tofacitinib was approved by the local ethics committee (“Comitato Buon Uso del Farmaco”) of the IRRCS Giannina Gaslini.
Availability of data and material
Data used during the current study are available from the corresponding author SR on reasonable request.
Competing interests
VN, SP, AIRG, PB, SR have no competing interests
CMC, SV and RP received speaker fee from SOBI
RC received speaker fee from Sobi and Novartis, consultancy from SOBI, Novartis and Eli Lilly.
AC received research support from Pfizer and speaker fee from Novartis
MG received speaker fee and consultancy from SOBI and Novartis
AR received consultancy and speaker fee from Abbvie, Alexion, Alfasigma, Angelini, BMS, Galapagos, Novartis, Pfizer, Reckitt-Benckiser, Roche, SOBI, research support from Novartis, Pfizer
Funding
No specific funding was received to carry out the here described work.
Authors' contributions
VN contributed to the conception of the study, collected clinical and radiological data, and wrote the first draft of the manuscript. SP and AIRG contributed to data collection. PB performed the type I IFN signature assays. MCC, RB, RC, SV, RP, AC, MG, AR provided critical input during the manuscript drafting and critically reviewed the final version of the manuscript. SR supervised the project, significantly contributed to the conception of the study and critically reviewed the manuscript throughtout the drafting process. All authors read and approved the final version of the manuscript.
Acknowledgements
The authors express their gratitude to the patient and her family for their cooperation and willingness to participate in this case report. We also acknowledge the exceptional care and support provided by the nursing staff, healthcare professionals, laboratory team and physicians at IRCCS Giannina Gaslini during the patient's treatment and follow-up.